Status: Closed
Activation Date: 1999AUG09
Closing Date: 2002MAY02
Phase: III
Description: The Influence of Letrozole on Serum Lipid Concentrations in Women with Primary Breast Cancer Who Have Completed Five Years of Adjuvant Tamoxifen -- A Companion Study to MA.17
Eligibility: MA.17 patients, who are non-hyperlipidemic and not taking lipid lowering agents.
Objective: To evaluate the effects of letrozole on serum lipid parameters in post-menopausal women treated with letrozole or placebo following at least five years of adjuvant tamoxifen therapy for breast cancer.
Participation: Limited to MA.17 participants
Lay Description: The purpose of this optional part of the MA.17 study, called a 'companion study', is to evaluate the effects of Letrozole / Placebo on the levels of certain fats in the blood. The collection of extra blood samples to look at changes in fat levels in the blood is an important but optional part of the MA.17 study in North America.
Primary Publication Show
Other Publications Show
Inventory
Hide Tissue Samples
| Disease Site | Trial Code | Patients Accrued | Patients - Blocks | Patients - Slides | Patients - Blocks and/or Slides |
| BREAST | MA17L | 347 | 0 | 0 | 0 |
(Core size is 0.6 mm)
Hide
Fluid Samples| Disease Site | Trial Code | Patients Accrued | TMA Blocks | Patients on TMA Blocks |
| BREAST | MA17L | 347 | 0 | 0 |
| Disease Site | Trial Code | Patients Accrued | Patients - Whole Blood | Patients - Cellular Component of Blood | Patients - DNA extracted from Blood | Patients - RNA extracted from Blood | Patients - Plasma | Patients - Serum | Patients - Urine | Patients - Buccal |
| BREAST | MA17L | 347 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |